Circulating miR-29c-3p is downregulated in patients with acromegaly
Open Access
- 30 August 2021
- journal article
- research article
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (4) , 2081-2086
Abstract
MiRNAs control various biological functions such as cell proliferation, differentiation, signaling pathways, apoptosis and metabolism. Recently, it has been shown that there is a relationship between changes in miRNA expression and the development of acromegaly. Studies are needed to identify new disease-specific miRNAs. The aim of the current study is to evaluate plasma miR-29c-3p, miR-31-5p and miR-18a-5p steady-state levels in acromegaly. Another aim is to investigate whether there is a difference in the levels of these miRNAs in patients with inadequate control and controlled acromegaly with somatostatin analog (SSA) therapy. These miRNAs targeting the IGF-1 gene were determined by in silico estimation. The study included 30 healthy controls (HC) and 20 patients with acromegaly. Anterior pituitary functions and disease activities of patients with acromegaly were evaluated at the time of study. The miR-29c-3p, miR-31-5p and miR-18a-5p levels were measured using quantitative Real-Time PCR (RT-qPCR). The expression level of miR-29c-3p was significantly lower in patients with acromegaly compared to the HC group (p<0.001). This downregulation was more pronounced in patients with inadequately controlled acromegaly than in patients with acromegaly controlled with SSA therapy (p=0.016). Univariate logistic regression analysis results showed that down regulation of miR-29c-3p expression increases the risk of developing acromegaly [OR (95% Cl)=1.605 (1.142-2.257), p=0.006]. There was no significant difference between the groups in terms of miR-31-5p and miR-18a-5p expression levels (p=0.375 and p=0.649, respectively). Plasma miR-29c-3p expression level is downregulated in patients with acromegaly, and this is more pronounced in patients with inadequate control.Keywords
This publication has 13 references indexed in Scilit:
- MicroRNAs and Target Genes in Pituitary AdenomasHormone and Metabolic Research, 2018
- p53 target miR-29c-3p suppresses colon cancer cell invasion and migration through inhibition of PHLDB2Biochemical and Biophysical Research Communications, 2017
- Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistancePituitary, 2016
- Expression and Significance of Circulating MicroRNA-31 in Lung Cancer PatientsMedical Science Monitor, 2015
- Acromegaly: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2014
- MicroRNAs as Biomarkers in Pituitary TumorsNeurosurgery, 2014
- MicroRNAs-based network: A novel therapeutic agent in pituitary adenomaMedical Hypotheses, 2012
- Differential expression of microRNAs in GH-secreting pituitary adenomasDiagnostic Pathology, 2010
- A Consensus on Criteria for Cure of AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 2010
- Somatostatin agonists for treatment of acromegalyMolecular and Cellular Endocrinology, 2008